Invivyd (IVVD) announced that the SPEAR Study Group has issued their consensus recommendation for a clinical study design to evaluate the effects of monoclonal antibody, mAb, therapy on Long COVID. The recommendation will be presented for consideration to RECOVER-TLC, an NIH initiative devoted to testing potential treatments for Long COVID. Formed by leading investigators in the field, the SPEAR Study Group is focused on designing studies that explore the role of persistent viral reservoirs or circulating spike protein in driving Long COVID. The study group’s proposed clinical study centers on anti-SARS-CoV-2 spike protein monoclonal antibodies designed to be broadly neutralizing, including VYD2311, as potential therapies for people suffering from Long COVID or Post-Vaccination Syndrome.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd’s Promising Position in the Antibody Market: Buy Rating Supported by Strong Data and Financial Growth
- Invivyd Raises $53.5 Million in Public Offering
- Invivyd 50M share Spot Secondary priced at 52c
- Invivyd Reports Strong Revenue Growth Amid Strategic Advances
- Closing Bell Movers: Nordson up 5% after Q3 earnings beat